VOLUNTARY ANNOUNCEMENT - THREE RESEARCH RESULTS OF "TQC3721 (PDE3/4 INHIBITOR)" AND "TQC2731 (TSLP MONOCLONAL ANTIBODY)" WILL BE PRESENTED AT ERS 2024

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

INTERIM DIVIDEND FOR 2024

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARINOMA

NOTIFICATION OF BOARD MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024

VOLUNTARY ANNOUNCEMENT - ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG CULMERCICLIB CAPSULE "CULMERCICLIB (TQB3616)"